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Abstract: Age-related macular degeneration (AMD) is the leading cause of irreversible loss of vision and 
decrease in quality of life in the elderly. A large number of molecular crossroads between cell death, 
phagocytosis and inflammation have been described in AMD. The different forms of cell death - apoptosis, 
anoikis, autophagy, necrosis, necroptosis and pyroptosis, have all been studied under different circumstances in 
the retina and in AMD pathology. Much less is known about the clearance of these dying cells by non-
professional (living retinal pigment epithelial (RPE) cells) and professional (macrophages and dendritic cells) 
phagocytes. The molecular synapse between the dying cells and the phagocytes is far from complete in 
relevance to AMD. Gene polymorphism of the phagocytic bridging molecules and those involved in 
inflammation and angiogenesis further complicate the lock-and-key theory in the clearance of dying cells in 
AMD. The present review gives an overview of the different risk factors, cell death types and clearance 
mechanisms in the retina, and their implications to inflammation and angiogenesis in AMD. A correlation of the 
genetic factors affecting AMD to those of other neurodegenerative diseases (Alzheimer’s, Huntington and 
Parkinson’s) is also attempted here.  
                
Keywords: cell death, apoptosis, autophagy, phagocytosis, inflammation, gene polymorphism, 
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Background of AMD 
 
Age-related macular degeneration (AMD) is a major 
cause of visual loss in people over 50 worldwide. It causes 
irreversible loss of central vision and significant decrease in 
quality of life of the elderly [1, 2]. Two major forms of 
AMD are being recognized in a simplified way: dry or early 
form (also known as geographic atrophy (GA)) and wet or 
late form (hallmarked by appearance of choroidal 
neovascularizations (CNVs)) based upon the absence or 
presence of drusen (yellow deposits) and/or fluid or 
neovascularizations, respectively, at the macula. The dry 
form of AMD is the most common and proceeds with 
thinning or atrophy of the retinal pigment epithelial (RPE) 
cells of the macula and deposition of drusen. Patients with 
the dry form of the disease in general do not lose fully their 
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reading vision [3, 4]. The wet form of AMD is characterized 
by a growth of abnormal blood vessels from the choroid into 
the retina via penetration of the Bruch’s membrane. Only 
about 10% of the people with macular degeneration develop 
the wet form of the disease, which is likely to cause severe 
visual loss over quite a short time - sometimes even months. 
AMD represents a major and growing public health problem 
in developed countries due to the ever increasing ageing 
population [5, 6]. 
 
Risk factors for AMD 
 
It is now clear, AMD turns manifest in the presence 
of external or specific environmental- as well as internal risk 
factors such as smoking [7], high blood pressure, high 
cholesterol level, obesity, or being light skinned, light eye-
colored, female subject. The disorder is more common in 
urban communities. The phenotype of early AMD reflects 
the influence of all these factors, while late AMD may be 
influenced by specific genes involved or suspected to be 
involved in the disease etiology, although full cause-and-
effect relationship to AMD has not been proven yet [5, 8-
10]. 
 
Cell death type and inflammation in AMD pathogenesis 
 
Until recently, apoptosis and necrosis were the only 
two major types of cell death described in the retina of AMD 
patients [11, 12]. Pyroptosis and autophagy have not been 
observed in oxidative stress-induced cell death in the retina 
[12]. More recently, however, our group and collaborators 
have detected autophagy in human eyes suffering from 
AMD [13]. The autophagy activation was hereby found 
important in the clearance of ELAVL1/HuR-mediated 
accumulation of SQSTM1/p62 during proteasomal inhibition 
of human RPE (hRPE) cells. In addition, autophagy and 
heterophagy dysregulation could be blamed for the RPE 
dysfunction and the development of AMD [2]. Hypoxia-
inducible factor (HIF) is known as the master regulator of 
hypoxia-induced cellular adaptation that is involved in the 
nuclear factor kappa beta (NFκB) signaling and the 
autophagic protein clearance system [14]. NOD-like receptor 
family, pyrin domain containing 3 (NLRP3) inflammasome 
activation in the RPE cells during pathogenesis of advanced 
AMD [15-18] suggests involvement of the inflammasome 
complex and caspase-1 activation, which together means 
presence of pyroptosis as a cell death modality in retinal 
cells. Indeed, different stimuli, like endoplasmatic reticulum 
(ER) stress inducers, tumor necrosis factor alpha (TNFα), 
ATP and lipopolysaccharide (LPS) can all activate caspase-1 
and -5 in primary cultured hRPE cells and in telomerase 
immortalized hRPE cells [19]. The zinc chelator (TPEN) can 
cause cell death in monkey retinal cells coupled with 
activation of cytosolic calpains and mitochondrial caspase 
pathways, but without ER stress [20]. Caspase inhibiton is 
not enough in preventing photoreceptor cell death, 
supporting the findings that not only apoptosis occurs in 
retinal or RPE detachment. In fact, the overlap between the 
different cell death pathways is very much prominent in the 
retina, the cell morphology appearance being similar to 
necrosis during RPE detachment, although autophagy also 
gets activated under such conditions [21]. When the caspase 
pathway is blocked, receptor interacting protein (RIP) 
kinases promote necrosis and overcome apoptosis inhibition 
[22]. Programmed necrosis or necroptosis is a necrosis-like 
cell death in retinal cells which is rather RIP-3-dependent 
[12] (supported by unpublished data from our in vitro studies 
on ARPE-19 and primary hRPE cells). RIP-3 is also 
involved in the ischemic stress response in the retina [23] 
and plays a central role in rescuing photoreceptor cell death 
in blind zebrafish [24]. Necroptosis can be efficiently 
blocked by necrostatins in ARPE-19 cells [25-28], in 
particular, Nec-1, 3 and 5 [12]. RIP-1-dependent necroptosis 
is less apparent in ARPE-19 cells, since Nec-1 has no effect 
on the RIP-1 kinase activity, but pro-inflammatory stimuli as 
those by TNFα can activate it (unpublished data). Oxidative 
stress-induced necrotic cell death in the retinal cells by H2O2 
treatment is rather controversial and can be prevented by 
Nec-1, but not by caspase inhibitor Z-VAD-FMK, without 
affecting apoptotic cell death [12]. An interesting association 
of RIP-7 (also known as leucine rich repeat kinase 2 
(LRRK2)) to neurodegenerative disease pathogenesis, in 
particular Parkinson’s disease, is due to a major genetic 
defect or a dominant missense mutation in this gene [29, 30]. 
 
Phagocytic clearance of dying cells and the role of 
macrophages and dendritic cells in AMD pathology 
 
Photoreceptors and RPE cells found at the edge of 
AMD atrophy die by apoptosis [31]. The atrophy propagates 
as the area of apoptosis expands, contributing to a 
development of visual loss as more and more retinal cells 
die. The dead cells’ debris in the eye is potentially dangerous 
material which needs removal. The process of clearance can, 
however, obstruct the physiological engulfment of the 
photoreceptor outer segments (POS) which occurs on a daily 
basis and is essential for keeping the retinal homeostasis in a 
balanced state. The importance of the phagocytosis carried 
out by RPE cells has been described some 40 years ago [32]. 
An insufficient clearance of dying retinal cells can lead to 
degeneration and inflammation [32, 33]. Not much is 
known, however, about the clearance of other types of dying 
cells in the retina such as autophagic, pyroptotic and 
necroptotic RPE cells. 
In dry AMD, dead cells’ debris from anoikic (cells 
detached from their extracellular matrix (ECM)) and 
apoptotic dying RPE cells gets engulfed by non-professional 
phagocytes (neighboring live RPE cells) in a highly efficient 
way as shown by our recent findings with ARPE-19 [34] and 
primary hRPE cells in vitro (unpublished data). Probably, 
other alternative routes of cell death lead to non-professional 
phagocytosis in the dry form of AMD, since intact, healthy 
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Figure 1. Molecules involved at the phagocytic synapse in the retina. Blue font represents genes in which SNPs have been 
associated with AMD. Abbreviations: ADAMTS9, a-disintegrin and metalloproteinase with thrombospondin motifs-9; ApoE, 
Apolipoprotein E; B3GALTL, beta 1,3-galactosyltransferase-like; Bal1, B-agressive lymphoma-1 protein; C3, complement 
component 3; CFB and CFH, complement factor B and H; CX3CL1, C-X3-C motif ligand 1; CX3CR1, C-X3-C motif receptor 1; 
DOCK180-ELMO, dedicator of cytokinesis-engulfment and cell motility protein; ECM, extracellular matrix; FAK, focal adhesion 
kinase; Gas6, Growth arrest-specific 6; HTRA1, high temperature requirement factor A1; InsP3, inositol-1,4,5-triphosphate; MCP-1, 
monocyte chemotactic protein-1; MFG-8, milk fat globule-8; PKC, Protein kinase C; PL, phospholipid; PLA2, phospholipase A2; 
POS, photoreceptor outer segment; PS, phosphatydil serine; RAC1, Ras-related C3 botulinum substrate; RPE, retinal pigment 
epithelium; SMUG1, single-strand selective monofunctional uracil-DNA glycosylate; TAM kinase, TYRO3, AXL, Mer kinase; TF, 
transferring; THBS1,thrombospondin 1;TGFβ, tumor growth factor beta; VEGF-A, vascular endothelial growth factor-A; UNG: 
Uracil-DNA glycosylate. 
 
eyes, have impenetrable tissue barriers to cellular 
components, while professional phagocytes (macrophages 
and dendritic cells (DCs)) cannot reach the dead cells under 
such conditions. 
In wet AMD, however, new vessels arise through the 
blood-retinal barrier, which bring close interaction between 
the RPE and retinal vascular cells. These new vessels are 
highly penetrable and leaky, thus professional phagocytes 
arrive at the scene and induce low-grade inflammation [35]. 
In this form of AMD, the macrophages and DCs bind to 
apoptotic cells, thus suppressing inflammation, while the 
clearance of autophagic dying cells might cause an 
inflammatory response [36]. The uptake of autophagic dying 
cells may happen in two ways: either by involvement of 
phosphatidylserine (PS) on the surface of the dying cells and 
engulfment by non-professional phagocytes (RPE) or in PS-
independent way during engulfment by macrophages 
(Figure 1) [37]. In vitro data suggest that macrophages 
activated in this way secrete pro-inflammatory cytokines 
such as IL-6, TNFα, IL-8 and IL-10 (Figure 1)[37]. 
Autophagic dying cells engulfed by macrophages after LPS 
induction, abolish the TNFα, IL-6 and IL-8 secretion, but not 
the IL-1β secretion (through caspase-1 activation). 
Moreover, macrophages secrete ATP after engulfing 
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autophagic dying cells; blockage of potassium (K+) efflux 
abolishes the IL-1β secretion from the phagocytic cells. 
Altogether, a possible downstream pro-inflammatory 
activation by the clearance of autophagic dying cells seems 
to be present during engulfment by macrophages [36]. 
Non-circulatory or resident macrophages (microglia) 
as well as DCs can also be present in the uveal tract of the 
eye. Homing or migration of these cells to the choroidal-
retinal border is independent of the CXC3 chemokine 
receptor 1 (CX3CR1) in normal young mice [38]. Forrester 
et al. identified two types of DCs in the choroid based upon 
their motility/migratory profile: relatively motile, large 
MHC class IImid DCs, and small MHC class IIhi cells capable 
of forming clusters [38]. Based on their different capacity 
for translocation to secondary lymphoid tissue, a different 
role for each is suggested. When choroidal DCs are co-
cultured with macrophages and choroidal cell preparations, 
their antigen presenting function increases as opposed to 
freshly isolated DCs. The response to stress, such as 
infection or ageing process (i.e. AMD) is, therefore, 
dependent upon other resident myeloid cells as well [39, 40]. 
The phagocytic capacity of macrophages towards dying RPE 
cells can be enhanced by triamcinolone (TA) ([34]; 
unpublished data), while substances causing elevation in 
cyclic AMP (cAMP) [41, 42], phosphodiesterase inhibitors 
(through cytoskeletal dysruptions) and lysosomotropic 
agents [43] as well as prostaglandins can decrease the rate of 
POS debris clearance (Figure 1). Exposure of cultured RPE 
cells originating from RCS rats to carbachol increases the 
intracellular concentration of inositol triphosphate and 
enhances the phagocytosis of bound POS [44], although this 
finding could not be confirmed by other studies [45].  
The phagocytosis carried out by RPE cells requires 
specific binding of the integrin receptor αvβ5 (Itgαvβ5) to 
POS and internalization of the complex (Figure 1). In fact, 
no other phagocytic cells than RPEs use this receptor for 
binding and internalization of the engulfed material [46]. 
Phospholipase A2 has been found to contribute in the 
recycling of the POS by ARPE-19 cell as well [47]. 
Moreover, growth-arrest-specific protein 6 (Gas6), a 
Vitamin K-dependent serum protein, similar to Protein S 
existing in the hemostatic system, can induce POS 
phagocytosis and turnover in a Mer-dependent manner [48-
50]. The redundancy of these molecules proves the 
importance of this circadian process [51]. The large plethora 
of molecules involved in the phagocytic synapse between 
RPE cells and/or macrophages as phagocytes, on one hand, 
and POS or dying RPE cells, on the other, are summarized in 
Figure 1. 
Lack or failure of phagocytosis may lead to drusen 
accumulation and later development of AMD [35] due to 
ECM detachment or anoikis of the RPE cells. Similar to 
retinal detachment, RPE detachment and cell death may 
induce production of cytokines and chemokines such as 
TNFα and monocyte chemoattractant protein-1 (MCP-1), 
which can mediate activation of macrophages and microglial 
cells. Chronically activated inflammatory cells can then 
infiltrate into the outer nuclear layer of the retina and 
stimulate photoreceptor cell death similar to how it happens 
in retinal detachment [52, 53]. 
 
Genes involved at the retinal phagocytic interface 
 
The apopto-phagocytic interface which is also known 
as “third synapse” consists of very complex “eat-me” and 
“don’t-eat-me” molecules found on the surface of 
engulfed/dying cells, factors released by these cells, bridging 
apopto-phagocytic molecules and effectors on the side of the 
phagocytes (Figure 1). RPE cells can secrete the 
glycoprotein milk fat globule-EGF8 (MFG-8) which can 
further activate the Itgαvβ5 [54-56] and therefore activate 
the intracellular signaling cascade involving focal adhesion 
kinases (FAK) [57]. Besides the aforementioned binding of 
Itgαvβ5 found on the surface of RPE cells to POS, efficient 
clearance of POS/dying cells in the retina needs involvement 
of so called TAM (Tyro 3, Axl and Mer-receptor Tyrosine 
Kinases (MerTK)) receptors expressed on the surface of 
RPE cells [58]. The latter molecules are related to some 
retinal dystrophies including retinitis pigmentosa [51]. 
Selective upregulation of the MerTK receptor via the 
Itgαvβ5-FAK signalling cascade, and decreased expression 
of the AXL receptor tyrosine kinase as well as 
thrombospondin-1 [59] on the surface of retinal phagocytes 
has been documented previously. Activation of MerTK 
results in intracellular free calcium release via the inositol-
1,4,5-triphosphate (InsP3) pathway [57]. The process of 
internalization of POS/dying cells in the retina is also 
dependent upon the scavenger receptor CD36 found on the 
surface of phagocytic cells (RPE and macrophages) [60-62]. 
Transforming growth factor-beta (TGFβ) can regulate 
human RPE phagocytosis by influencing the protein kinase 
C (PKC)-dependent pathway [63]. 
 
Correlations of genetic factors found in AMD and other 
neurodegenerative diseases 
 
AMD is characterized by abnormal accumulation of 
cell material at the base of the RPE cell layer. Extensive 
deposits can be a result of RPE cell dysfunction, 
disintegration of photoreceptor cells or failure of phagocytic 
activity that put the individual to a higher risk of developing 
AMD. Drusen formation is accompanied by appearance of 
immunomodulatory proteins, thus local pro-inflammatory 
events. Presence of chronic localized inflammation together 
with progressive neurodegeneration is observed in patients 
suffering from Alzheimer’s disease (AD). The two diseases 
share risk factors, such as ageing, hypercholesterolemia, 
hypertension, smoking [7] and obesity [5]. Amyloid beta 
(Aβ) peptide - a major component of the plaques in AD has 
been demonstrated in retinal drusen as a substructural 
vesicular component [64]. AD-related apolipoprotein ApoE 
is also present in deposits concerning both conditions as well 
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[65]. Imbalance in the Aβ angiogenesis-related factors in 
RPE cells and lack of neprilysin (Aβ degrading enzyme) in 
mice causes drusen formation similar to that observed in 
human AMD [66]. Aβ is implied to co-localize with proteins 
of the complement system in the amyloid structures, thus 
contributing to local pro-inflammatory changes [64] in both 
AD and AMD. Aβ is a target for immunotherapy of AD and 
the approach has been extended to AMD as well. 
Systemically administered anti-Aβ increases its elimination 
from the retina and the brain, and electroretinography 
abnormalities cease to exist in a mouse model [67]. 
Although SNP associations in complement factor H (CFH), 
age-related maculopathy susceptibility protein 2 (ARMS2) 
and complement component 3 (C3) genes exist in AD, a 
different genetic model seems to be present in AMD, 
suggesting a different contribution of the complement 
activation in the two diseases - complement pathway 
induction is less pronounced in AD [68]. Logue et al. reports 
no significant overlapping of genetic association between 
AD and AMD in the form of SNPs [69]. 
The ageing processes of cells in the retina and the 
brain goes through similar signaling associations [5]. 
Molecular genetic findings reveal four micro RNAs 
(miRNA-9, miRNA-125b, miRNA-146a, miRNA155) as 
being upregulated in AMD and AD. These miRNAs silence 
brain and retinal cell-relevant family mRNAs, as well as the 
CFH gene, a negative regulator of the innate immunity and 
inflammatory response [70]. 
Oxidative stress, abnormal cellular homeostasis and 
chronic inflammation are common risk factors of age-related 
neurodegenerative diseases, therefore a similar pathogenesis 
could be associated in different conditions, such as 
Parkinson’s disease. In a retrospective cohort study 
conducted on Chinese patients, people diagnosed with late 
AMD had a 2.57 hazard ratio of developing Parkinson’s 
disease [71]. No study has been conducted to date to explore 
a connection between AMD and Huntington’s disease. 
 
Gene polymorphisms found in AMD 
 
The development of AMD is dependent on genetic 
and environmental factors. Polymorphism SNP studies 
reveal different loci associated with genetic risk to develop 
the condition as shown in Table 1. The strongest connection 
is with complement factor H (CFH) on 1q32 [72-78]. 
Tyr402His appears to be indicative of AMD pathogenesis. 
Diabetes, age, and gender in the presence of the homozygous 
C/C genotype in CFH carry an increased risk of AMD [73]. 
There are also several studies regarding a second major 
susceptibility gene PLEKHA1/LOC387715/HTRA1 [79] 
and Factor B polymorphism which play important roles in 
AMD [80]. Variations in genes of the complement system, 
such as complement 2 (C2/CFB) [81], C3 [82, 83] and CFI 
[84] are also linked to AMD [78-81]. 
APOE gene variants indicate risk for AMD: APOE-ε2 
allele elevates, while APOE-ε4 allele reduces the risk for 
developing AMD [73, 76, 85, 86]. Studies on a Chinese [85] 
and Hungarian population [76] show no evidence for 
association of APOE polymorphism with AMD. Moreover, a 
separate Hungarian study reports no link between the 
exudative and dry form of AMD and the polymorphisms in 
the APOE, CFI, FXIII and MERTK genes [76], but Gas6 
c.834+7G.A polymorphism appears to be protective, 
reducing the odds of wet type AMD to half [76]. 
Modest effect on AMD of loci variations in CETP, LIPC, 
TIMP3, VEGFA, TNFRSF10A, COL10A1, COL8A1, 
COL8A1/FILIP1L, SLC16A8, IER3/DDR1, TGFBR1, 
RAD51B, ADAMTS9/MIR548A2 and B3GALTL are also 
reported [87-90] (Table 1). 
Polymorphism in iron homeostasis genes is addressed 
in relation to risk for AMD development. GC SNP at 
rs4481157 and rs8177178 [91] decreases the risk of dry 
AMD, while GA genotype increases the risk of dry AMD 
and decreases it for wet AMD [91]. Chowers et al. 
demonstrates that transferrin expression is elevated in AMD 
patients with respect to a control group [92]. Serum 
transferrin level is also increased in the AMD group, but the 
total serum iron level is not changed [93]. 
Altered iron homeostasis in the retina can produce 
reactive oxygen species (ROS) contributing to oxidative 
stress. Higher concentration of iron is found in post-mortem 
AMD retinas (as compared to unaffected ones) in the 
photoreceptors, RPE and drusen [94]. Oxidative stress can 
induce damage in DNA and may affect DNA repair as well. 
This may lead to misincorporation of uracil to DNA 
controlled by DNA glycosylases. Polymorphism of the DNA 
repair genes SMUG1 and UNG is also shown to be related to 
AMD pathogenesis (Figure 1 and Table 1) [95]. The C/C 
genotype polymorphism of UNG is associated with an 
almost three-fold risk of atrophic AMD, while the T/T 
genotype is a protective polymorphism. Presence of the T 
allele of g.4235T>C together with A allele of c.-31A>G of 
SMUG1, however, poses higher risk for developing severe 
AMD. The C/C genotype of g.4235T>C SNP and G/G 
genotype of c.-31A>G polymorphism have a protective 
effect [95]. Progressive maculopathy, similar to AMD 
develops in retinas of patients suffering from hereditary 
aceruloplasminemia [31].  
Animal models with knocked-out ferroxidase 
ceruloplasmin (Cp) and homologous hephestin (Heph) have 
age-dependent iron accumulation followed by subretinal 
neovascularization and degeneration [96]. Revealing the 
mechanisms of iron homeostasis and prevention of iron 
overload in the retina may therefore be advantageous in the 
treatment of AMD. 
The HFE gene is expressed in RPE cells, so patients 
with hereditary haemochromatosis –a condition caused by a 
mutation in this gene - accumulate iron locally, predisposing 
the patient to AMD development. Under such conditions, 
iron-binding drugs can be useful in the prevention of iron 
overload [31]. 
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Variations in the fractalkine receptor CX3CR1 show 
association with progressive age-related conditions, such as 
atherosclerosis. There are two SNPs; V249I and T280M of 
this gene, with a higher allele frequency of the M280 being 
detected in AMD affected population versus controls. The 
M280 and I249 alleles can produce an abnormal CX3CR1-
CX3CL1 interaction and a decreased number of receptor 
sites [97, 98]. 
No effect of the TLR4 polymorphism in association 
with AMD is found in Indian patients [73]. SNPs in the 
SERPING-1 gene encoding complement factor 1 (C1) 
inhibitor, such as rs1005510 and rs2511989 show 
association to wet AMD, exerting a modest risk and a 
protective effect, respectively, in a study conducted on an 
American (Caucasian) population [99]. In contrast, a study 
conducted on Age-Related Eye Disease Study (AREDS) 
subjects shows no association between the SNPs in 
SERPING-1 and AMD, nor it finds any other risk variants of 
AMD-related genes [100]. 
Vascular endothelial growth factor (VEGF) and 
pigment epithelium-derived factor (PEDF) are the major 
regulators of angiogenesis, and polymorphisms in these 
genes can affect angiogenesis–related diseases in the eye 
[101]. There are known SNPs in the VEGF gene, such as 
+405C/G (rs2010963), -460 T/C (rs833061), +674 C/T 
(rs1413711), +936C/T (rs3025039, and -2578C/A 
(rs699947) in association with AMD. Polymorphisms -
460C/T (rs833061) and -634G>C (rs2010963) are associated 
with diabetic retinopathy. The C/T genotype of -460C>T 
increases the risk and occurrence of dry AMD, while the T/T 
genotype lowers it. Dry AMD also associates with the C/C 
genotype of -634G>C and together with the C/T genotype of 
-460C>T, the SNPs correlate with the appearance of AMD. 
The T/T-G/G and T/T-G/C genotypes are all protective for 
AMD, while C/T-G/G (C/C) genotype increases the risk of 
atrophic and exudative AMD as detected by a study 
performed on a Polish population [102, 103]. The VEGF 
+936 C/T [104] and CFH Y402H SNPs show strong 
correlation with wet AMD in a Chinese population [77]. 
SNPs in the genes VEGFA rs699947 and rs833061 and 
VEGFR2 rs2071559 do not affect the risk of acquiring AMD 
as detected by a study performed on a Spanish population. 
VEGFR2 rs2071559 polymorphism shows that carriers of a 
G/G genotype are more frequent in the subjects with AMD, 
but is not statistically significant after  Bonferroni correction 
[105]. Fang et al. supports these findings and shows no 
evidence of genetic risk as a cause of the SNPs, except for a 
rare haplotype in VEGFR2 for neovascular AMD [106]. 
 
Prospects for future and cell therapy in AMD 
 
To date, no effective therapy is available for treating 
the dry form of AMD, although antioxidants and omega-
fatty acids show positive effect on prolonging the onset of 
the disease (AREDS study and modified AREDS). Oral 
supplements determined from these studies (antioxidant 
vitamins C and E, lutein, zeaxanthin, and zinc) can reduce 
the risk of progression to advanced AMD. The use of 
antioxidants holds a future promise provided it goes through 
an evidence-based trial process; such attempts are also 
undertaken with the use of sulphur antioxidants, 
sulbutiamine and acetylcysteine (NAC) [107], canolol [108], 
paeoniflorin [109], clusterin [110], curcumin [111] and H2S 
[112, 113]. 
In the late stages of the dry form of AMD, preventing 
the RPE cell death through limiting oxidative stress-induced 
necrosis in these cells may hold promise through the use of 
necrostatins [12].  
In the wet form of AMD, inhibitors of the 
neovascularization process (ranibizumab, bevacizumab and 
VEGF Trap) [114-116] are all considered impressive drugs, 
although the frequency of injections is a drawback or a 
major cause of harmful side-effects. Alternatively, injection 
of external PEDF [117] or stimulation of its internal 
production is considered a promising way of blocking 
neovascularization. Alternatively, Ras pathway inhibitors are 
considered for treating wet AMD [118]. A secreted 
extracellular domain of the VEGF receptor-1, sFlt-1, which 
is a naturally occurring protein antagonist of the VEGF 
formed by alternative splicing of the pre-mRNA of the full-
length receptor is used successfully to achieve strong 
suppression of retinal or subretinal neovascularization in 
mice [119]. In addition, resolvins and protectins, which 
mediate a beneficial effect through preventing NF-κB 
signaling, are proposed as new targets for regulating the 
inflammatory responses in AMD [120]. 
An alternative way of preventing AMD is to enhance 
the phagocytic capacity by different glucocorticoid-steroid 
analogues (triamcinolone, dexamethasone) [34]. Potential 
use of specific agonists of the tyrosine kinase receptors, as 
well as complement- and anti-amyloid based therapies can 
also hold a future promise in AMD therapy. 
MicroRNAs serving as therapeutic targets focus on 
silencing miR-23, miR-24 and miR-27 [121, 122] to achieve 
repression of neovascularization. 
Cell therapy for AMD is based upon the use of a wide 
range of cells including both pluripotent stem cells and 
multipotent stem cells of fetal and adult origin. Restoring the 
damaged RPE layer in vivo [123], however, faces a cellular 
polarization problem remaining to be solved before 
transplantation. 
Finally, few experimental drugs for treating AMD 
undergo testing or clinical trials: α-5-β-1 integrin antibody 
fragment (Protein Design Labs, Fremont, CA), integrin 
antagonists (Jerini, Berlin, Germany), bFGF-2 vaccine 
(Entremed, Rockville, MD), isotretinoin (UCLA, Los 
Angeles, CA) and phosphodiesterase-5 inhibitor (Pfizer, 
Groton, CT). 
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Table 1. List of genetic loci affecting risk for developing AMD and short description about their role. SNPs that have been related to 
AMD are shown with minor allele frequencies (MAF).  
 
Chromosome 
location 
Gene/locus Most 
important 
SNPs related 
to AMD 
MAF Pathway relevant 
to AMD 
Function 
3p14.1 ADAMTS9 N.a. N.a. ECM The protein encoded by the gene is responsible for 
cleaving proteoglycans of the extracellular matrix, 
such as aggrecan, versican. 
19q13.32 APOE rs7412 
rs429358 
2: 0.14 
4: 0.08 
Lipid metabolism Protein-encoding gene; functions include binding, 
internalization and degredation of lipoproteins. 2 
allele brings forward the onset, while 4 delays 
development of AMD. 
10q26.13 ARMS2/HTRA1 rs10490924/ 
rs11200638 
0.3 Other Protein localized in the cytoplasma, encoded by 
ARMS2 gene is associated with age-related 
diseases. HTRA1 regulates IGF and TGF family 
signaling. 
13q12.3 B3GALTL N.a. N.a. Other Type 2 membrane protein, an enzyme responsible 
for the extension of O-fucosylglycan. 
6p21.33 C2/CFB rs9332739 
rs547154 
rs4151667 
rs641153 
0.03 
0.11 
0.03 
0.1 
Complement Serum glycoprotein, C2a is serine protease of the 
complement system; deficiencies have been 
associated with autoimmune conditions. Protective 
SNPs. 
19p13.3 C3 rs2230199 
rs1047286 
0.14 
0.16 
Complement Activated protein (C3a) mediates local 
inflammatory reponses; degranulation of mast cells, 
enhanced vessel permeability. 
16q13 CETP N.a. N.a. Lipid metabolism Transfers molecules relevant to lipoprotein 
metabolism, may affect susceptibility to 
atherosclerosis. 
1q31.3 CFH rs1061147 
rs1061170 
rs800292 
rs3753394 
0.37 
0.36 
<0.01 
<0.01 
Complement Regulation of complement activation via 
inactivation of C3b as a cofactor. 
4q25 CFI rs10033900 
rs13117504 
rs11726949 
0.49 
0.41 
0.28 
Complement Acts together with CFH, functions as a regulatory 
molecule in the complement system. 
6q22.1 COL10A1 rs1999930 0.14 ECM Encodes type x collagen whic is synthetized in 
cartilage, also associated to FAK signaling. 
3q12.1 COL8A1/FILIP1L rs13081855 
rs13095226 
0.06 
0.07 
ECM (COL8A1) 
angiogenesis 
(FILIP1L) 
Component of corneal (Descemet's membrane) and 
vessel endothelium, maintenance of vessel wall 
integrity. 
3p22.2 CX3CR1 rs3732378 
rs3732379. 
0.14 
<0.01 
Other Functions as a receptor for leukocytes for migration 
and adhesion. 
13q34 GAS6/AXLLG/AXSF rs8191974 0.27 Phagocytosis Interacts with AXL receptor tyrosine kinase, MerTK 
amd TYRO3. Involved in cell survival and 
proliferation. Protective SNP in wet AMD. 
6p21.33 IER3/DDR1 N.a. N.a. Apoptosis (IER3)/ 
ECM (DDR1) 
Encoded protein has a role in cell survival; DDR1 is 
involved in tyrosine kinase signaling pathways. 
15q21.3 LIPC rs10468017 0.2 Lipid metabolism Enzyme of HDL metabolism and lipoprotein uptake. 
14q24.1 RAD51B N.a. N.a. DNA-repair Involved in repair mechanisms during homologous 
recombination. 
22q13.1 SLC16A8 N.a. N.a. Other Membrane transport protein, carries 
monocarboxylates. 
12q13.13 SMUG1 rs3087404 0.38 DNA-repair Functions include elimination of uracil from DNA 
3q22.1 TF rs4481157 0.47 Other Tranports iron to proliferating cells. 
9q22.33 TGFBR1 N.a. N.a. Other Signal transduction of TGFβ from cell surface to the 
cytoplasm. 
22q12.3 TIMP/SYN3 rs9621532 N.a. ECM Has a role in ECM remodeling through inhibition of 
metalloproteinases. 
8p21.3 TNFRSF10A rs13278062 0.35 Apoptosis Receptor; transducer of death signaling. 
12q24.11 UNG rs2337395 0.39 DNA-repair Removes uracil from ssDNA. 
6p21.1 VEGFA rs833061 
rs2010963 
rs3025039 
0.36 
0.33 
0.14 
Angiogenesis Main functions include mediation of angio- and 
vasculogenesis; vessel permeabilization and 
endothelial cell growth 
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Conclusion 
 
AMD is a complex, multifactorial disease which 
involves many pathways ranging from cell death, 
phagocytosis, inflammation and angiogenesis. Favoring or 
stimulating one pathway may have countercoup effect on 
another related pathway, therefore, much caution should be 
used in deciding which short or long term therapy is the best 
for treating the different stages of the disease. Population 
differences in gene polymorphism pose a great challenge 
and deserve higher attention in making personalized 
medicine work in the future.  
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